ClinicalTrials.gg
RecruitingNCT07485608Updated Nov 5, 2026

Reducing Lead Dust Exposure in Older Housing

An interventional study of portable air filtration systems in Exposure to Toxic Dust and Elevated Blood Lead Levels, sponsored by Michigan State University. Recruiting at 1 site in United States. Open to participants aged Up to 7 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Michigan State University · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Dec 2022, registered May 2023).
  • Started Dec 2022; still recruiting 3 years 11 months later.
Updated Nov 5, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
Up to 7 Years
Sex
All
01

Study summary

The objective of this study is to assess the effectiveness of portable air filtration (PAF) for mitigating lead dust exposures and reducing childhood blood lead levels in older housing.

Read the detailed description

In close collaboration with local health departments, this project will enroll 40 participants who (1) reside in housing built before 1970, and (2) have children under six years of age with blood lead levels (BLL) >5 μg/dL. Specific objectives include (1) assess reduction of Pb dust exposure via the intervention, (2) assess the ability of PAF to reduce childhood BLL indirectly via reductions in Pb dust exposure, and (3) develop evidence-based exposure reduction guidance for wider public use of PAF. The project team will measure Pb levels in (1) suspended dust, (2) floor dust, and (3) children's blood before the start and finish of the two-month-long intervention as well as at the midpoint.

02

Conditions studied

  • Exposure to Toxic Dust
  • Elevated Blood Lead Levels
03

In context

Lead sponsor

Michigan State University is the lead sponsor of 143 studies on the registry; 27 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 7 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • child under seven years of age with BLL >5 µg/dL,
  • child must reside in housing built before 1978, and
  • child must sleep at home during participation in the two month-long study.

Exclusion criteria

Exclusion Criteria:

  • anything in child's health history that could affect the study results, or
  • any circumstance that could interfere with guardian's/parent's ability to consent and/or participate in the study.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    air filtration systems

    Portable air filtration units will be kept running in homes for two months.

    Other: portable air filtration systems

Interventions

  • Otherportable air filtration systems

    Two portable air filtration units placed in subjects' homes (one in child's bedroom and one in living room) will be kept running for two months.

06

What researchers measure

Primary outcomes

  1. Change in blood lead level

    change in blood lead level (in ug/dL).

    Time frame: After two months at the end of the intervention

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2022 to primary completion in Jul 2026, 43 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2023
First posted
Mar 20, 2026
StartActual
Dec 1, 2022
Primary completionActual
Jul 3, 2026
CompletionEst.
Nov 30, 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 31, 2026→Jul 3, 2026 (actual)
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Primary completion Jul 31, 2026→Jul 3, 2026 (now actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07485608
Responsible party
Masako Morishita (Associate Professor, Michigan State University) — Principal investigator
First posted
Mar 20, 2026
Start date
Dec 1, 2022
Primary completion
Jul 3, 2026
Completion
Nov 30, 2026 (estimated)
Last update
Nov 5, 2026

Study contacts

Tuan Nguyen, BS
Contact
nguye620@msu.edu
517-884-2043
Masako Morishita, PhD
Contact
tomoko@msu.edu
517-884-0463

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion